Sarafan ChEM-H

The Nucleus at Sarafan ChEM-H is a cluster of labs led by industry in areas like drug development and clinical research. This seed grant awards $50,000 to start new Nucleus collaborations in Medicinal Chemistry, Metabolomics, Macromolecular Structure, CryoEM, or High-Throughput Screening.

To train more researchers to better produce, purify, and  characterize proteins, the Macromolecular Structure Knowledge Center (MSKC) at Sarafan ChEM-H is accepting proposals from scientists to start or enhance a protein characterization project.

Sarafan ChEM-H seeks to support small teams of clinicians and molecular scientists/engineers who seek to test bold hypotheses or validate the utility of a new tool in disease diagnosis or management using samples from human subjects.

The IMA, CDCM and CCT, seek to accelerate the development of promising and innovative early-stage translational stem cell and gene therapies that fill unmet clinical needs.

IMA is accepting proposals for assay development projects to create and optimize miniaturized assays in 384-well microplate format for use in high-throughput, small-molecule screens. 

ChEM-H seeks to support research projects driven by junior investigators and aimed at testing molecular hypotheses in human subjects. Submissions must include an MD or MD/PhD investigator and a junior investigator.

The Innovative Medicines Accelerator (IMA) aims to accelerate the translation of scientific discoveries at into new therapeutics that impact human health. This RFP supports treatments for spinal muscular atrophy and other neuromuscular diseases.

The Innovative Medicines Accelerator (IMA) aims to accelerate the prototyping of innovative medicines, and to enable hypothesis-driven studies on human subjects. This RFP seeks to leverage Stanford Clinical and Translational Research Unit.

The Innovative Medicines Accelerator (IMA) aims to accelerate the prototyping of innovative medicines, and to enable hypothesis-driven studies on human subjects. This RFP seeks to leverage Stanford infrastructure to address the COVID-19 pandemic

The Innovative Medicines Accelerator (IMA) aims to accelerate the prototyping of innovative medicines, and to enable hypothesis-driven studies on human subjects. This RFP seeks to leverage Stanford infrastructure to address the COVID-19 pandemic